Saturday, 31 October 2026European Markets

TEIXEIRA DUARTE Stock Is 21% Up In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of TEIXEIRA DUARTE (PSI: TDSA.LS) rose by a staggering 21.95% in 10 sessions from 0.07 € to 0.09 € at 19:30 EST on Thursday, after two sequential sessions in a row of gains. PSI is jumping 0.39% to 5,926.73 €, following the last session's downward trend.

About TEIXEIRA DUARTE

Teixeira Duarte, S.A. operates in the construction, concessions and services, real estate, hospitality, distribution, and automotive sectors in Portugal and internationally. The company is involved in various construction activities, including geotechnical engineering and rehabilitation, buildings, infrastructures, and metalworking, as well as underground, railway, and maritime works; and the provision of concessions and services in various business areas, such as facilities management, facilities services, environment, and education. It also develops real estate properties comprising residential, corporate, trade and service, and logistics facilities; and operates 8 hotels, including 2 located in Portugal, 3 in Angola, and 3 in Mozambique covering a total of 2,460 beds and 1,230 rooms. In addition, the company distributes food products through MAXI and bompreço grocery store chains; and furniture and household products under the Dakaza brand, as well as engages in catering business and develops health and wellness area with Farmácia Popular. Further, it sells light and heavy-duty vehicles, motorcycles, equipment, and tires and lubricants; and provides technical assistance. The company was founded in 1921 and is headquartered in Oeiras, Portugal.

Earnings Per Share

As for profitability, TEIXEIRA DUARTE has a trailing twelve months EPS of -0.03 €.

Volume

Today's last reported volume for TEIXEIRA DUARTE is 115500 which is 1128.05% above its average volume of 111752.

More news about TEIXEIRA DUARTE (TDSA.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com